
Blog
Interleukin-1 blockade with high-dose Anakinra in patients with COVID-19
‘The Lancet Rheumatology’ has published an important treatment success using high-dose Anakinra, which is biological disease modifying anti-rheumatic drug (biological DMARD). This retrospective cohort study of

